Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lobeglitazone + glimepiride
- Development stage
- Phase 1
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lobeglitazone + glimepiride is an **oral fixed-dose combination anti-diabetic medication** used for the management of type 2 diabetes mellitus. **Lobeglitazone** is a thiazolidinedione-class insulin sensitizer that selectively activates peroxisome proliferator-activated receptor gamma (PPARγ), enhancing insulin sensitivity in adipose tissue and muscle. **Glimepiride** is a sulfonylurea-class insulin secretagogue that stimulates insulin release from pancreatic beta cells by binding to ATP-sensitive potassium channels, leading to cell depolarization and insulin exocytosis. This dual mechanism addresses both insulin resistance and insufficient insulin secretion, resulting in improved glycemic control for patients unresponsive to monotherapy. The combination is taken orally, typically once daily, and is primarily indicated for adults with type 2 diabetes mellitus[1][4][5].
- Other names
- lobeglitazone sulfate + glimepiridelobeglitazone sulfate + glimepiride fixed-dose combination
02
Targets
KATP channel (ATP-sensitive potassium channel)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)PTPN1 (Protein tyrosine phosphatase 1B)
Beyond the preview
Go deeper on lobeglitazone + glimepiride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lobeglitazone + glimepiride.